Web10 feb 2024 · In this issue of Blood, Cavo et al 1 confirm the prognostic value of minimal residual disease (MRD) negativity in multiple myeloma (MM) by conducting a robust … Web14 ott 2024 · Multiple myeloma (MM) is a treatable plasma cell cancer with no cure. Clinical evidence shows that the status of minimal residual disease (MRD) after treatment is an …
IMWG on MRD Response & Assessment Int Myeloma Fn
Web27 mag 2024 · In this study, the minimal residual disease (MRD) levels in patients with multiple myeloma (MM) were assessed by comparing the new 8-color single-tube multiparameter flow cytometry method... Web20 feb 2024 · Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now often treated in the newly diagnosed and relapsed and/or refractory settings with monoclonal antibodies targeting lineage-specific markers used either alone or in rationally designed combination regimens. Among these are the anti-CD38 antibodies … indian express helpline
Minimal residual disease in multiple myeloma: why, when, …
Web26 nov 2024 · Assessing measurable residual disease (MRD) has become a standard procedure in many hematologic malignancies, 1-4 but the lack of effective therapies for multiple myeloma (MM) delayed the interest to perform MRD studies in this disease until the past decade. Although initial data were obtained using low-sensitive and … WebHighlights This is a high-sensitivity flow cytometry test for detection of minimal residual myeloma cells, post treatment It uses adopted EuroFlow guidelines and Cytognos … Web13 apr 2024 · The big difference is that the CAR T-cell product is given on a one-time basis with dramatic benefits, while the bispecific therapy is given as ongoing treatment. The current problem with the CAR T-cell product is that there is limited availability because there have been supply shortages with the materials required to manufacture the CAR T ... indian express heaton norris